Conclusively, this study represents the first for the anti-cholinesterase activities and chemical profiling of A. lucidior and A. procera leaves, alongside the potential of normethyl budmunchiamine K as a lead drug for designing new AChE inhibitors for Alzheimer’s disease treatment. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.